Arthritis & Rheumatology最新文献_第3页

Comparative Real-World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet's Disease. 免疫调节疗法预防beharret病葡萄膜炎复发的比较实际效果。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-15 DOI: 10.1002/art.43382

Zhenyu Zhong,Jiayi Wang,Lan Xia,Shixiang Jing,Yujie Lai,Tao Cai,Peizeng Yang

{"title":"Comparative Real-World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet's Disease.","authors":"Zhenyu Zhong,Jiayi Wang,Lan Xia,Shixiang Jing,Yujie Lai,Tao Cai,Peizeng Yang","doi":"10.1002/art.43382","DOIUrl":"https://doi.org/10.1002/art.43382","url":null,"abstract":"PURPOSETo evaluate comparative effectiveness of cyclosporine, interferon alfa-2a, and adalimumab for the prevention of uveitis relapse in Behçet's disease in real-world settings.METHODSWe emulated a target trial involving adult patients with Behçet's disease uveitis who initiated cyclosporine, interferon alfa-2a, or adalimumab between April 10, 2008, and August 1, 2024, and were followed up until September 10, 2024. We applied overlap weighting to balance patient characteristics across treatment groups and emulate randomization at baseline. The primary outcome was the annualized relapse rate of uveitis during treatment with study therapy.RESULTSThe cohort comprised 716 cyclosporine users, 193 interferon alfa-2a users, and 103 adalimumab users. The estimated mean annualized relapse rate of uveitis was 0.95 (95%, 0.82 to 1.10) with cyclosporine, 0.52 (95%, 0.40 to 0.69) with interferon alfa-2a, and 0.28 (95%, 0.19 to 0.43) with adalimumab. Patients treated with cyclosporine experienced more relapses than those treated with adalimumab (incidence rate ratio [IRR], 3.36 [95% CI, 2.23 to 5.05]; mean difference, 0.66 [95% CI, 0.48 to 0.85]; P<0.001) or interferon alfa-2a (IRR, 1.81 [95% CI, 1.37 to 2.40]; mean difference, 0.42 [95% CI, 0.22 to 0.62]; P<0.001). The relapse rate was higher with interferon alfa-2a than with adalimumab (IRR, 1.86 [95% CI, 1.16 to 2.97]; mean difference, 0.24 [95% CI, 0.05 to 0.43]; P=0.011).CONCLUSIONIn Behçet's disease, interferon alfa-2a was associated with a reduction in uveitis relapse compared with cyclosporine, while adalimumab demonstrated a stronger association with reduced relapse than interferon alfa-2a.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"36 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to: "Gut Microbiota Typing and Donor Factors Shape Fecal Microbiota Transplantation Response in Psoriatic Arthritis". 对“银屑病关节炎患者肠道菌群分型和供体因素影响粪便菌群移植反应”的回应。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-15 DOI: 10.1002/art.43394

Maja S Kragsnaes,Panpan Qin,Jens Kjeldsen,Karsten Kristiansen,Torkell Ellingsen

引用次数: 0

Less Is More: Hematologic Safety and Sustained Efficacy of a Modified Low-dose Etoposide Regimen in MAS. 少即是多：改良的低剂量依托泊苷治疗MAS的血液学安全性和持续疗效。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-15 DOI: 10.1002/art.43390

Zijun Ma,Xiaoquan Rao,Yingying Wei,Wei Tu,Jixin Zhong

引用次数: 0

Gut Microbiota Typing and Donor Factors Shape Fecal Microbiota Transplantation Response in Psoriatic Arthritis. 肠道菌群分型和供体因子影响银屑病关节炎患者粪便菌群移植反应。

IF 10.9 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-15 DOI: 10.1002/art.43392

Bi-Yu Gao, Shiuan-Chih Chen

引用次数: 0

"Negative" finding supports two-hit model. “否定”发现支持两次命中模型。

IF 10.9 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-15 DOI: 10.1002/art.43385

Ronald van Vollenhoven

引用次数: 0

Successfully treated mandibular osteomyelitis by TNF inhibitor in SAPHO syndrome. TNF抑制剂成功治疗SAPHO综合征的下颌骨髓炎。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-14 DOI: 10.1002/art.43375

Seiya Oba,Tadashi Hosoya,Kota Yokoyama,Hirofumi Tomioka,Hiroyuki Harada,Shinsuke Yasuda

引用次数: 0

More Than Just ANA: Antibody Sialylation May Tip the Balance in Autoimmunity. 不仅仅是ANA：抗体唾液化可能会改变自身免疫的平衡。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-11 DOI: 10.1002/art.43379

Raquel M Centeio,Taia T Wang

引用次数: 0

Reply to Letter to the Editor: "Systemic autoimmune rheumatic disease risk is associated with long-term exposure to fine particulate matter". 回复致编辑的信：“系统性自身免疫性风湿病风险与长期暴露于细颗粒物有关”。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-11 DOI: 10.1002/art.43378

Sasha Bernatsky,Naizhuo Zhao

引用次数: 0

Where we Live matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States. 我们生活的地方很重要：美国银屑病关节炎的各种疾病负担和治疗模式。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-11 DOI: 10.1002/art.43377

Brittany Banbury,Sharon Dowell,Christopher Jenkins,Emily E Holladay,Fenglong Xie,Jingyi Zhang,Grace C Wright,Jeffrey R Curtis,Gail S Kerr

{"title":"Where we Live matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States.","authors":"Brittany Banbury,Sharon Dowell,Christopher Jenkins,Emily E Holladay,Fenglong Xie,Jingyi Zhang,Grace C Wright,Jeffrey R Curtis,Gail S Kerr","doi":"10.1002/art.43377","DOIUrl":"https://doi.org/10.1002/art.43377","url":null,"abstract":"OBJECTIVETo evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.METHODSA cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90th percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated. Logistic regression models were used to identify regional correlates of HDA and comorbidity.RESULTSOf 32,732 PsA RISE patients, 58.8% were White females [mean (SD) age 57.7(13.5) years] with private insurance (60%); 55.8% resided in the South. A majority (81.8%) had a BMI of ≥25, highest in the Midwest (32.4 ±7.8). Women, despite prevalent HDA, received less bDMARD therapy. Both HDA and ADI ≥80 were more prevalent in the South and Midwest. Compared to the Northeast, Midwest patients had a higher burden of comorbidity [aOR:1.59, 95% CI 0.98 - 2.59] with frequent use of prednisone in conjunction with conventional DMARDs (31.3% vs. Northeast 20.5%, South 13.6%, West 17.6%). Uveitis affected 1.2% of the cohort. Only 14 (7.1%) and 20 (10.1%) RISE practices provided care for half of all Medicaid and high deprivation patients, respectively.CONCLUSIONSPsA disease characteristics and care vary across the US, with higher-than-expected prednisone use, and unequal provider care burden in some regions. Further work is needed to assess the impact of varied regional care on disease outcomes.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"14 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on: Time-Dependent Effect of Prophylactic Trimethoprim-Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Target Trial Emulation Study. 预防性甲氧苄啶-磺胺甲恶唑对抗中性粒细胞细胞质抗体相关血管炎严重感染发生率的时间依赖性影响：一项目标试验模拟研究。

IF 10.9 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-11 DOI: 10.1002/art.43373

Ivana Capuano, Eleonora Riccio, Pasquale Buonanno, Antonio Pisani

引用次数: 0